Diabetic patients and kidney protection: an attainable target.
J Hypertens Suppl
; 26(2): S3-7, 2008 Jun.
Article
en En
| MEDLINE
| ID: mdl-18979716
Diabetic nephropathy, the major cause of end-stage renal disease in the world occurs as a result of both metabolic and haemodynamic insults, thus emphasizing the importance of optimizing glycaemic and blood pressure control in patients with or at risk of this disorder. The mainstay of antihypertensive therapy is now inhibition of the renin-angiotensisn system involving the use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. The appropriate blood pressure level for the commencement of these drugs and what should be the achieved blood pressure in individuals with diabetes remain controversial. Promising new therapies are currently under preclinical investigation or in early stage clinical trials, and hopefully these newer agents, probably used as adjunct therapies, will further improve the prognosis of individuals with diabetes with early or overt renal disease.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Ensayos Clínicos Controlados Aleatorios como Asunto
/
Diabetes Mellitus Tipo 2
/
Nefropatías Diabéticas
/
Hipertensión Renal
/
Riñón
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Revista:
J Hypertens Suppl
Asunto de la revista:
ANGIOLOGIA
Año:
2008
Tipo del documento:
Article
País de afiliación:
Australia
Pais de publicación:
Reino Unido